Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
| Condition(s) | DLBCL - Diffuse Large B Cell Lymphoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy. |
| Who can participate | Inclusion Criteria: 1. Histological diagnosis of DLBCL\&LBCL 2. Planned treatment with guideline-based first-line therapy 3. Patient's consent 4. All genders, Patient age ≥ 18 years 5. Ability to consent Exclusion Criteria: 1. Treatment with R-CHOP/-like regimens already started 2. Relationship of dependence/ direct employment with the investigator 3. Active HIV-infection 4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Lead sponsor | University Medical Center Goettingen |
| Locations | Göttingen, Lower Saxony, Germany |
| Start date | 2024-06-20 |
| NCT ID | NCT06526065 |
| Official listing | https://clinicaltrials.gov/study/NCT06526065 |